Literature DB >> 18188078

Objective measurement of work absence and on-the-job productivity: a case-control study of US employees with and without gastroesophageal reflux disease.

Peter Wahlqvist1, Richard A Brook, Sara M Campbell, Mari-Ann Wallander, Anne M Alexander, Jim E Smeeding, Nathan L Kleinman.   

Abstract

OBJECTIVE: To establish an association between gastroesophageal reflux disease (GERD) and increased work absence, as well as reduced productivity while at work, by using objective productivity measurements.
METHODS: Retrospective case-control analysis of a database containing US employees' administrative health care and payroll data for employees (N = 11,653 with GERD; N = 255,616 without GERD) who were enrolled for at least one year in an employer-sponsored health insurance plan.
RESULTS: Employees with GERD had 41% more sick leave days (P < 0.0001), 59% more short-term disability days (P < 0.0001), 39% more long-term disability days (P = 0.1910), 48% more workers' compensation days (P < 0.0001), 4.4% lower objective productivity per hour worked (P = 0.0481), and 6.0% lower annual objective productivity (P = 0.0391) than the employees without GERD.
CONCLUSIONS: GERD is associated with a significant impact on employees' work absence and productivity while at work as measured using objective data.

Entities:  

Mesh:

Year:  2008        PMID: 18188078     DOI: 10.1097/JOM.0b013e31815dba5a

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  11 in total

1.  Acid control cannot be improved with a modified-release formulation of a proton pump inhibitor compared with twice-daily dosing of the conventional formulation.

Authors:  Kerstin Röhss; Clive Wilder-Smith; Sara Bokelund-Singh; Mohamed Sagar; Péter Nagy
Journal:  Dig Dis Sci       Date:  2010-03-18       Impact factor: 3.199

2.  Effects of structured follow-up and of more effective acid inhibitory treatment in the management of GORD patients in a Swedish primary-care setting: a randomized, open-label study.

Authors:  Rickard Ekesbo; Svante Sjöstedt; Heléne Sörngård
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

3.  The burden of disrupting gastro-oesophageal reflux disease: a database study in US and European cohorts.

Authors:  Samira Toghanian; Peter Wahlqvist; David A Johnson; Susan C Bolge; Bengt Liljas
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

4.  Burden of gastro-oesophageal reflux disease in patients with persistent and intense symptoms despite proton pump inhibitor therapy: A post hoc analysis of the 2007 national health and wellness survey.

Authors:  Samira Toghanian; David A Johnson; Nils-Olov Stålhammar; Frank Zerbib
Journal:  Clin Drug Investig       Date:  2011-10-01       Impact factor: 2.859

5.  [Use of health resources and loss of productivity in gastroesophageal reflux disease: results of a cross-sectional study in a primary care setting in Spain].

Authors:  Javier Nuevo; Mónica Tafalla; Javier Zapardiel; J P Gisbert
Journal:  Aten Primaria       Date:  2011-03-05       Impact factor: 1.137

Review 6.  Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults.

Authors:  Kate McKeage; Stephanie K A Blick; Jamie D Croxtall; Katherine A Lyseng-Williamson; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Patient factors predictive of 24-h pH normalization following endoluminal gastroplication for GERD.

Authors:  Yashodhan S Khajanchee; Michael Ujiki; Christy M Dunst; Lee L Swanstrom
Journal:  Surg Endosc       Date:  2009-05-09       Impact factor: 4.584

8.  Impact of gastro-oesophageal reflux disease on work productivity despite therapy with proton pump inhibitors in Germany.

Authors:  M Gross; U Beckenbauer; J Burkowitz; H Walther; B Brueggenjuergen
Journal:  Eur J Med Res       Date:  2010-03-30       Impact factor: 2.175

9.  Partial response to proton pump inhibitor therapy for GERD: observational study of patient characteristics, burden of disease, and costs in the USA.

Authors:  Nils-Olov Stålhammar; Brennan M Spiegel; Helena Granstedt Löfman; Maria Karlsson; Peter Wahlqvist; Jørgen Næsdal; M Todd Nelson; Nicolas Despiégel
Journal:  Pragmat Obs Res       Date:  2012-12-05

10.  Impact of gastroesophageal reflux disease on work absenteeism, presenteeism and productivity in daily life: a European observational study.

Authors:  Javier P Gisbert; Alun Cooper; Dimitrios Karagiannis; Jan Hatlebakk; Lars Agréus; Helmut Jablonowski; Javier Nuevo
Journal:  Health Qual Life Outcomes       Date:  2009-10-16       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.